Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00169572|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : May 10, 2010
|Condition or disease||Intervention/treatment||Phase|
|Nausea and Vomiting Chemotherapy-Induced||Drug: Aprepitant Drug: Ondansetron Drug: GW679769 Drug: Dexamethasone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||492 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||See Detailed Description|
|Study Start Date :||February 2005|
- Drug: Aprepitant
- Drug: Ondansetron
- Drug: GW679769
- Drug: Dexamethasone
- The number of subjects who do not experience vomiting, retching or nausea over a 5 day period following the initiation of chemotherapy.
- Routine physical exam findings, vital signs, routine clinical laboratory tests, clinical monitoring and/or observation, and adverse events reporting.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00169572
Show 51 Study Locations
|Study Director:||GSK Clinical Trials, MD||GlaxoSmithKline|